financetom
Business
financetom
/
Business
/
Tempus AI Q1 Earnings: Revenue Beat, EPS Beat, Raised FY Guidance, Shares Surge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tempus AI Q1 Earnings: Revenue Beat, EPS Beat, Raised FY Guidance, Shares Surge
May 26, 2025 2:20 AM

Tempus AI Inc ( TEM ) reported first-quarter financial results Tuesday after the market close. Here’s a look at the key details from the report.

Q1 Earnings: Tempus AI ( TEM ) reported first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision medicine and patient care company reported a first-quarter adjusted loss of 24 cents per share, beating analyst estimates for a loss of 27 cents per share, according to Benzinga Pro.

Total revenue was up 75.4% year-over-year as genomics revenue grew 88.9% year-over-year to $193.8 million. Data and services revenue grew 43.2% to $61.9 million, led by Insights (data licensing), which grew 58% year-over-year.

Tempus AI ( TEM ) highlighted multi-year strategic collaborations with AstraZeneca and Pathos, resulting in an additional $200 million in data licensing and model development fees over the next three years. The company had approximately $151.6 million in cash and equivalents at the quarter's end.

“The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage,” said Eric Lefkofsky, founder and CEO of Tempus AI ( TEM ).

“Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos. We believe this is just the beginning as more and more healthcare providers and life science companies embrace AI.”

Outlook: Tempus AI ( TEM ) raised its full-year 2025 revenue guidance from $1.24 billion to $1.25 billion for its consolidated Tempus and Ambry Genetics business, which represents approximately 80% annual growth.

The company continues to expect full-year 2025 adjusted EBITDA of $5 million, versus a full-year adjusted EBITDA loss of $104.7 million in full-year 2024.

Tempus AI ( TEM ) executives will further discuss the company’s quarterly results on a conference call set for 4:30 p.m. ET

TEM Price Action: Tempus AI ( TEM ) shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday, according to Benzinga Pro.

Read Next:

Beyond The Numbers: 9 Analysts Discuss Tempus AI Stock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
JPMorgan nears deal to take over Apple's credit card program, WSJ reports
JPMorgan nears deal to take over Apple's credit card program, WSJ reports
Jul 29, 2025
(Reuters) -JPMorgan Chase is in advanced talks to take over Apple's credit card program from Goldman Sachs, the Wall Street Journal reported on Tuesday, citing people familiar with the matter. ...
Wegovy maker Novo's profit warning triggers $70 billion share rout
Wegovy maker Novo's profit warning triggers $70 billion share rout
Jul 29, 2025
COPENHAGEN (Reuters) -Investors knocked $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. Novo named Maziar Mike Doustdar as its new chief executive, turning to an experienced insider to revive sales and a share...
JX Luxventure Group Unit Gets $15 Million Cross-Border Contract for Duty-Free Goods in China
JX Luxventure Group Unit Gets $15 Million Cross-Border Contract for Duty-Free Goods in China
Jul 29, 2025
10:41 AM EDT, 07/29/2025 (MT Newswires) -- JX Luxventure Group ( JXG ) said its Jin Xuan Holding Group unit secured a $15 million contract for the purchase of duty-free cross-border products by Qingxiang Cross-Border E-Commerce. The products include duty-free skincare, health supplements and lifestyle goods, Haikou, China-based JX Luxventure ( JXG ) said Tuesday in a statement. Qingxiang Cross-Border...
Copyright 2023-2026 - www.financetom.com All Rights Reserved